Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review

IMPORTANCE: A thorough understanding of the optimal role and sequence of agents for treatment of multiple myeloma (MM) requires knowledge of the use and rate of postprotocol therapies in randomized clinical trials (RCTs). OBJECTIVES: To examine the proportion of MM RCTs that reported postprotocol th...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohyuddin, Ghulam Rehman, Koehn, Kelly, Abdallah, Al-Ola, Goodman, Aaron M., Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082314/
https://www.ncbi.nlm.nih.gov/pubmed/33909053
http://dx.doi.org/10.1001/jamanetworkopen.2021.8084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082314/
https://www.ncbi.nlm.nih.gov/pubmed/33909053
http://dx.doi.org/10.1001/jamanetworkopen.2021.8084

Ejemplares similares